Developer docs
API playgroundTry for free, no card

Search company profiles

Entrada Therapeutics

Full company profile

uuid000075s

Namestring
Entrada Therapeutics
Legal namestring
Entrada Therapeutics, Inc.
Websiteurl
entradatx.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Entrada Therapeutics is a clinical-stage biopharmaceutical company founded in 2016-2017 and headquartered in Boston, Massachusetts, that develops intracellular therapeutics built on its proprietary Endosomal Escape Vehicle (EEV™) Platform — a library of cyclic cell-penetrating peptides designed to enable efficient intracellular delivery of oligonucleotides, proteins, and other therapeutic modalities into tissues previously considered inaccessible and undruggable. Preclinical data on file indicates approximately half of EEV-therapeutics reach their intended intracellular target, compared with only ~1-2% for conventional biological therapeutics, and the platform has demonstrated near-complete dystrophin restoration in skeletal muscle in Duchenne muscular dystrophy (DMD) preclinical models.

The company's clinical pipeline focuses on neuromuscular and inherited retinal diseases, led by four EEV-Oligonucleotide candidates for exon 44, 45, 50, and 51 skip-amenable Duchenne muscular dystrophy (ENTR-601-44, -45, -50, -51), of which ENTR-601-44 and ENTR-601-45 are in Phase 1/2 (ELEVATE-44-201 and ELEVATE-45-201) studies across the U.S., U.K., and EU. The myotonic dystrophy type 1 (DM1) program VX-670 (formerly ENTR-701) is out-licensed to Vertex Pharmaceuticals, which holds global development, manufacturing, and commercialization rights; Entrada also has discovery-stage ENTR-801 targeting USH2A for inherited retinal diseases. The company is publicly traded on NASDAQ under ticker TRDA with a market capitalization of approximately $531M as of April 2026, 86.39% institutional ownership, $254.9M cash and marketable securities (March 31, 2026), and a disclosed runway into Q3 2027.

Entrada's revenue model is currently driven entirely by collaboration revenue from the December 2022 Vertex Pharmaceuticals agreement, which delivered $224M upfront, $26M equity investment, and up to $485M in potential milestones. Q1 2026 collaboration revenue was $0.9M versus $20.6M in Q1 2025, reflecting milestone-driven lumpiness, and the company is pre-commercial with no approved products. Operating losses are widening (Q1 2026 net loss of $39.7M) as the company invests in multiple clinical readouts. The May 7, 2026 ELEVATE-44-201 Cohort 1 readout showing only a 2.36% dystrophin increase triggered a 57.27% one-day stock decline to $6.85/share and multiple securities-fraud investigations by Pomerantz, Schall, and Holzer & Holzer, materially elevating both clinical-program and litigation risk for the franchise.

Short descriptiontext

Entrada Therapeutics is a Boston-based, NASDAQ-listed clinical-stage biopharmaceutical company developing intracellular therapeutics for Duchenne muscular dystrophy, myotonic dystrophy type 1, and inherited retinal diseases using its proprietary cyclic cell-penetrating peptide EEV™ Platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
intracellular therapeutics, cell-penetrating peptides, Duchenne muscular dystrophy, myotonic dystrophy treatment, rare disease therapeutics
Industry2 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Blood and Organ Banks621991
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration Revenue
TypeLicensing Royalties
Description

Revenue recognized under the strategic collaboration and license agreement with Vertex Pharmaceuticals for the development of EEV-therapeutics for myotonic dystrophy type 1 (DM1), including VX-670 and additional DM1-related research. Q1 2026 collaboration revenue was $0.9 million versus $20.6 million in Q1 2025. Entrada received $224 million upfront and a $26 million equity investment, with potential for up to $485 million in milestone payments.

globenewswire.com
2Future Product Sales (Pipeline, Pre-Commercial)
TypeOne Time License
Description

Entrada is a clinical-stage biopharmaceutical company with no approved commercial products. Future revenue is expected to derive from commercialization of EEV-therapeutic product candidates for Duchenne muscular dystrophy (ENTR-601-44, -45, -50, -51), myotonic dystrophy type 1 (VX-670 with Vertex), and inherited retinal diseases (ENTR-801: USH2A and undisclosed programs).

entradatx.com
Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1Clinical-stage biopharmaceutical company with no publicly disclosed pricing for therapeutics (pre-commercial)
ModelOtherBilling cadenceOther
Notes

Salary bands for U.S. job postings are publicly disclosed; product pricing not yet applicable.

entradatx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1EEV (Endosomal Escape Vehicle)
Description

Proprietary therapeutic platform of cyclic cell-penetrating peptides used to deliver oligonucleotides and other modalities intracellularly.

entradatx.com
+1 more record
Core offering1 text field

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing intracellular therapeutics built on its proprietary Endosomal Escape Vehicle (EEV™) Platform — a library of cyclic cell-penetrating peptides engineered to deliver oligonucleotides and other therapeutic modalities into cells while escaping endosomal clearance. Its pipeline spans clinical-stage product candidates for Duchenne muscular dystrophy (ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51), the Vertex-partnered DM1 program VX-670/ENTR-701, and a discovery-stage program ENTR-801 for USH2A-related inherited retinal diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ~50% of EEV-therapeutics reach intended intracellular target vs ~1-2% of conventional biological therapeutics (preclinical)
+3 more records
Product overview1 text field

Entrada Therapeutics is a clinical-stage biopharmaceutical company built around a single unifying core technology — its proprietary Endosomal Escape Vehicle (EEV™) Platform — from which a modular portfolio of intracellular therapeutic product candidates is generated. The EEV™ Platform (cyclic cell-penetrating peptides) supports clinical-stage product candidates ENTR-601-44 and ENTR-601-45 in exon 44- and exon 45-skip amenable Duchenne muscular dystrophy (DMD), earlier-stage DMD candidates ENTR-601-50 and ENTR-601-51, the Vertex-partnered DM1 program VX-670 (formerly ENTR-701), and discovery-stage ENTR-801 for USH2A inherited retinal disease. Around these therapeutics, Entrada also operates the DREAMS Grant Program, a corporate-giving initiative that funds Duchenne-focused non-profits. The platform-plus-modular-candidates architecture means every named therapeutic leverages the same EEV delivery system while targeting different intracellular disease drivers.

Product and service7 records
1EEV™ Platform
Categorycore platform
Description

Proprietary Endosomal Escape Vehicle (EEV) Platform — a library of cyclic cell-penetrating peptides designed to enable efficient intracellular delivery of therapeutic modalities (oligonucleotides, proteins) into a wide range of organs, tissues and cells, engaging disease-causing targets previously considered inaccessible and undruggable.

2ENTR-601-44
Categoryclinical-stage product candidate
Description

EEV-Oligonucleotide therapeutic candidate for exon 44 skip-amenable Duchenne muscular dystrophy; being evaluated in the Phase 1/2 ELEVATE-44-201 study. Designed to address the underlying genetic cause of Duchenne to allow muscle cells to produce functional dystrophin.

3ENTR-601-45
Categoryclinical-stage product candidate
Description

EEV-Oligonucleotide therapeutic candidate for exon 45 skip-amenable Duchenne muscular dystrophy; being evaluated in the Phase 1/2 ELEVATE-45-201 study. DMC recommended Cohort 2 initiation at 10 mg/kg in June 2026.

4ENTR-601-50
Categorypreclinical product candidate
Description

EEV-Oligonucleotide therapeutic candidate for exon 50 skip-amenable Duchenne muscular dystrophy; preclinical-stage with efficacy data presented at OTS 2025 and World Muscle Society 2025.

5ENTR-601-51
Categorypreclinical product candidate
Description

EEV-Oligonucleotide therapeutic candidate for exon 51 skip-amenable Duchenne muscular dystrophy; preclinical-stage with efficacy poster presented at MDA Clinical & Scientific Conference 2026.

6VX-670 (ENTR-701)
Categoryclinical-stage product candidate (partner-led)
Description

EEV-Oligonucleotide therapeutic candidate for myotonic dystrophy type 1 (DM1); being developed under a global collaboration with Vertex Pharmaceuticals, which is responsible for global development, manufacturing and commercialization. Currently in global Phase 1/2 clinical development.

7ENTR-801
Categorydiscovery-stage product candidate
Description

Discovery-stage program targeting USH2A for inherited retinal diseases, built on the EEV Platform.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-12-08
Description

Global collaboration to develop Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1), including Entrada's lead candidate ENTR-701/VX-670. Entrada received $224 million upfront, $26 million equity investment, and is eligible for up to $485 million in milestone payments. Vertex is responsible for global development, manufacturing, and commercialization. The four-year research collaboration has Entrada advancing certain research activities related to VX-670 and additional DM1-related research. Program is in global Phase 1/2 development with enrollment and dosing underway.

Strategic tierMinorTypeGTM or Marketing Partner
Description

2025 DREAMS Grant recipient — U.S.-based nonprofit headquartered in Massachusetts serving individuals affected by Duchenne muscular dystrophy. Grant funds Camp Promise year-round no-cost program for individuals aged 18+ living with Duchenne and other neuromuscular disorders.

Strategic tierMinorTypeGTM or Marketing Partner
Description

2025 DREAMS Grant recipient — Italian nonprofit supporting individuals with Duchenne and Becker muscular dystrophy. Grant funds home-based care and teleconsultation services for families in underserved regions of Southern Italy.

Strategic tierMinorTypeGTM or Marketing Partner
Description

2024 DREAMS Grant recipient supporting the CureDuchenne International Outreach Program to expand awareness, diagnosis, treatment and support for individuals affected by Duchenne in Nepal, Uganda, China and other countries throughout 2024-2025.

5The Little Hercules Walking Strong Foundation (LHF)
Strategic tierMinorTypeGTM or Marketing Partner
Description

2024 DREAMS Grant recipient supporting individualized case management services for the Duchenne community and subsidizing the cost of translation services for families whose first language is not English.

entradatx.com
6Walking Strong
Strategic tierMinorTypeGTM or Marketing Partner
Description

2024 DREAMS Grant recipient expanding one-on-one mental wellness and life coaching, access to mobility and assistive devices, and canine support animals for individuals affected by Duchenne.

entradatx.com
7The Akari Foundation
Strategic tierMinorTypeGTM or Marketing Partner
Description

2023 DREAMS Grant recipient — Hispanic-focused nonprofit educating and empowering the Hispanic community about rare diseases with a focus on Duchenne, providing resources, awareness, advocacy and education entirely in Spanish.

entradatx.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

2023 DREAMS Grant recipient — nonprofit private practice led by Dr. Diana Castro providing care to neuromuscular patients from minority backgrounds who are underserved, uninsured or underinsured; grant funds hiring of first mental health professional.

Strategic tierMinorTypeGTM or Marketing Partner
Description

2023 DREAMS Grant recipient — nonprofit patient advocacy organization fighting to end Duchenne by helping those living with the condition lead longer, stronger lives; grant supports work to address disparity in access to care and research opportunities.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Digital accessibility partner conducting user and expert reviews, WCAG 2.1 AA audits, role-based training, ongoing accessibility support and expert standards guidance for entradatx.com.

Strategic tierMinorTypeOthers
Description

GDPR / UK GDPR external data protection representatives appointed by Entrada Therapeutics. EDPO is the EU GDPR representative (Brussels, Belgium); EDPO UK Ltd is the UK GDPR representative (London, UK). Available for data subject requests via online forms.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Community-based partner organizations supporting Entrada's diversity, equity, and inclusion initiatives across Boston, Cambridge, and the biotech sector. Provide community, mentorship, and challenge the status quo.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sarepta is the leading commercial DMD franchise with approved exon-skipping PMOs (eteplirsen, golodirsen, casimersen) and Elevidys gene therapy. Directly comparable to Entrada as both companies develop exon-skipping oligonucleotide therapies for DMD populations including exons 44, 45, 50, and 51.

TypeDirect peer
Description

Avidity's antibody-oligonucleotide conjugate (AOC) platform has reported ~25% dystrophin production in DMD patients, setting the current competitive bar that Entrada's EEV-oligonucleotide approach must beat in the same exon-skipping populations.

TypeDirect peer
Description

Dyne is developing oligonucleotide therapeutics for DMD using its FORCE™ platform targeting muscle. It is a direct competitor in exon-skipping DMD and shares Entrada's focus on muscle-targeted nucleic acid delivery.

TypeDirect peer
Description

PepGen develops conjugated oligonucleotides for DMD and DM1 using its Enhanced Delivery Oligonucleotide (EDO) platform. Directly comparable to Entrada on modality (oligonucleotide) and on overlap in DMD and DM1 indications.

TypeDirect peer
Description

Solid Biosciences is developing next-generation DMD therapies including SGT-003 (a gene therapy) and oligonucleotide approaches. It competes in the same DMD patient population targeted by Entrada's ENTR-601 series.

TypeDirect peer
Description

Capricor is developing CAP-1002 (cell therapy) and deramiocel for DMD. It is a relevant comparable as a clinical-stage DMD company targeting the same patient population with a different therapeutic modality, competing for the same physician/patient mindshare and capital.

TypeBroad incumbent
Description

Vertex is Entrada's DM1 collaboration partner (VX-670) and a $26M equity holder. Comparable as a strategic partner/incumbent in DM1 and as a broader rare disease biopharma that could acquire Entrada or expand the relationship.

TypeBroad incumbent
Description

Ionis is the established antisense oligonucleotide platform company with multiple approved products (e.g., Spinraza for SMA). Comparable to Entrada on oligonucleotide modality and antisense approach, and as a potential acquirer of intracellular delivery technology.

TypeEmerging player
Description

AMO Pharma is developing tideglusib for DM1 (Phase 2/3). Relevant emerging competitor in the DM1 indication that Entrada/Vertex's VX-670 also targets.

TypeBroad incumbent
Description

BioMarin is an established rare disease biopharma with prior DMD exposure (Kyndrisa, discontinued) and a broad pipeline in neuromuscular and metabolic indications. Comparable as a larger incumbent that could partner with or acquire Entrada's EEV platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Entrada Therapeutics

Biopharmaceuticalsentradatx.com

Entrada Therapeutics is a Boston-based, NASDAQ-listed clinical-stage biopharmaceutical company developing intracellular therapeutics for Duchenne muscular dystrophy, myotonic dystrophy type 1, and inherited retinal diseases using its proprietary cyclic cell-penetrating peptide EEV™ Platform.

What Entrada Therapeutics does

Entrada Therapeutics is a clinical-stage biopharmaceutical company founded in 2016-2017 and headquartered in Boston, Massachusetts, that develops intracellular therapeutics built on its proprietary Endosomal Escape Vehicle (EEV™) Platform — a library of cyclic cell-penetrating peptides designed to enable efficient intracellular delivery of oligonucleotides, proteins, and other therapeutic modalities into tissues previously considered inaccessible and undruggable. Preclinical data on file indicates approximately half of EEV-therapeutics reach their intended intracellular target, compared with only ~1-2% for conventional biological therapeutics, and the platform has demonstrated near-complete dystrophin restoration in skeletal muscle in Duchenne muscular dystrophy (DMD) preclinical models.

The company's clinical pipeline focuses on neuromuscular and inherited retinal diseases, led by four EEV-Oligonucleotide candidates for exon 44, 45, 50, and 51 skip-amenable Duchenne muscular dystrophy (ENTR-601-44, -45, -50, -51), of which ENTR-601-44 and ENTR-601-45 are in Phase 1/2 (ELEVATE-44-201 and ELEVATE-45-201) studies across the U.S., U.K., and EU. The myotonic dystrophy type 1 (DM1) program VX-670 (formerly ENTR-701) is out-licensed to Vertex Pharmaceuticals, which holds global development, manufacturing, and commercialization rights; Entrada also has discovery-stage ENTR-801 targeting USH2A for inherited retinal diseases. The company is publicly traded on NASDAQ under ticker TRDA with a market capitalization of approximately $531M as of April 2026, 86.39% institutional ownership, $254.9M cash and marketable securities (March 31, 2026), and a disclosed runway into Q3 2027.

Entrada's revenue model is currently driven entirely by collaboration revenue from the December 2022 Vertex Pharmaceuticals agreement, which delivered $224M upfront, $26M equity investment, and up to $485M in potential milestones. Q1 2026 collaboration revenue was $0.9M versus $20.6M in Q1 2025, reflecting milestone-driven lumpiness, and the company is pre-commercial with no approved products. Operating losses are widening (Q1 2026 net loss of $39.7M) as the company invests in multiple clinical readouts. The May 7, 2026 ELEVATE-44-201 Cohort 1 readout showing only a 2.36% dystrophin increase triggered a 57.27% one-day stock decline to $6.85/share and multiple securities-fraud investigations by Pomerantz, Schall, and Holzer & Holzer, materially elevating both clinical-program and litigation risk for the franchise.

Entrada Therapeutics firmographics

Firmographics
Name
Entrada Therapeutics
Legal name
Entrada Therapeutics, Inc.
Website
https://entradatx.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Entrada Therapeutics is a Boston-based, NASDAQ-listed clinical-stage biopharmaceutical company developing intracellular therapeutics for Duchenne muscular dystrophy, myotonic dystrophy type 1, and inherited retinal diseases using its proprietary cyclic cell-penetrating peptide EEV™ Platform.
Ownership category
akta.pro rank

Entrada Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Blood and Organ Banks (621991)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Intracellular therapeutics
  • Cell-penetrating peptides
  • Duchenne muscular dystrophy
  • Myotonic dystrophy treatment
  • Rare disease therapeutics

Where Entrada Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Entrada Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Collaboration Revenue: Revenue recognized under the strategic collaboration and license agreement with Vertex Pharmaceuticals for the development of EEV-therapeutics for myotonic dystrophy type 1 (DM1), including VX-670 and additional DM1-related research. Q1 2026 collaboration revenue was $0.9 million versus $20.6 million in Q1 2025. Entrada received $224 million upfront and a $26 million equity investment, with potential for up to $485 million in milestone payments.
  2. Future Product Sales (Pipeline, Pre-Commercial): Entrada is a clinical-stage biopharmaceutical company with no approved commercial products. Future revenue is expected to derive from commercialization of EEV-therapeutic product candidates for Duchenne muscular dystrophy (ENTR-601-44, -45, -50, -51), myotonic dystrophy type 1 (VX-670 with Vertex), and inherited retinal diseases (ENTR-801: USH2A and undisclosed programs).

Pricing tiers

ModelBillingPrice
OtherOtherClinical-stage biopharmaceutical company with no publicly disclosed pricing for therapeutics (pre-commercial)

Go-to-market motion1 record

Distribution channels3 records

Entrada Therapeutics product offering

Product offering

Core offering

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing intracellular therapeutics built on its proprietary Endosomal Escape Vehicle (EEV™) Platform — a library of cyclic cell-penetrating peptides engineered to deliver oligonucleotides and other therapeutic modalities into cells while escaping endosomal clearance. Its pipeline spans clinical-stage product candidates for Duchenne muscular dystrophy (ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51), the Vertex-partnered DM1 program VX-670/ENTR-701, and a discovery-stage program ENTR-801 for USH2A-related inherited retinal diseases.

Product overview

Entrada Therapeutics is a clinical-stage biopharmaceutical company built around a single unifying core technology — its proprietary Endosomal Escape Vehicle (EEV™) Platform — from which a modular portfolio of intracellular therapeutic product candidates is generated. The EEV™ Platform (cyclic cell-penetrating peptides) supports clinical-stage product candidates ENTR-601-44 and ENTR-601-45 in exon 44- and exon 45-skip amenable Duchenne muscular dystrophy (DMD), earlier-stage DMD candidates ENTR-601-50 and ENTR-601-51, the Vertex-partnered DM1 program VX-670 (formerly ENTR-701), and discovery-stage ENTR-801 for USH2A inherited retinal disease. Around these therapeutics, Entrada also operates the DREAMS Grant Program, a corporate-giving initiative that funds Duchenne-focused non-profits. The platform-plus-modular-candidates architecture means every named therapeutic leverages the same EEV delivery system while targeting different intracellular disease drivers.

Differentiator

Problem solved

Functional benefit

Brands

  • EEV (Endosomal Escape Vehicle): Proprietary therapeutic platform of cyclic cell-penetrating peptides used to deliver oligonucleotides and other modalities intracellularly.
  • DREAMS Grant Program

Products and services

  • EEV™ Platform Proprietary Endosomal Escape Vehicle (EEV) Platform — a library of cyclic cell-penetrating peptides designed to enable efficient intracellular delivery of therapeutic modalities (oligonucleotides, proteins) into a wide range of organs, tissues and cells, engaging disease-causing targets previously considered inaccessible and undruggable.
  • ENTR-601-44 EEV-Oligonucleotide therapeutic candidate for exon 44 skip-amenable Duchenne muscular dystrophy; being evaluated in the Phase 1/2 ELEVATE-44-201 study. Designed to address the underlying genetic cause of Duchenne to allow muscle cells to produce functional dystrophin.
  • ENTR-601-45 EEV-Oligonucleotide therapeutic candidate for exon 45 skip-amenable Duchenne muscular dystrophy; being evaluated in the Phase 1/2 ELEVATE-45-201 study. DMC recommended Cohort 2 initiation at 10 mg/kg in June 2026.
  • ENTR-601-50 EEV-Oligonucleotide therapeutic candidate for exon 50 skip-amenable Duchenne muscular dystrophy; preclinical-stage with efficacy data presented at OTS 2025 and World Muscle Society 2025.
  • ENTR-601-51 EEV-Oligonucleotide therapeutic candidate for exon 51 skip-amenable Duchenne muscular dystrophy; preclinical-stage with efficacy poster presented at MDA Clinical & Scientific Conference 2026.
  • VX-670 (ENTR-701) EEV-Oligonucleotide therapeutic candidate for myotonic dystrophy type 1 (DM1); being developed under a global collaboration with Vertex Pharmaceuticals, which is responsible for global development, manufacturing and commercialization. Currently in global Phase 1/2 clinical development.
  • ENTR-801 Discovery-stage program targeting USH2A for inherited retinal diseases, built on the EEV Platform.

Quantifiable outcome

  • ~50% of EEV-therapeutics reach intended intracellular target vs ~1-2% of conventional biological therapeutics (preclinical)
  • +3 more outcomes

Companies that use Entrada Therapeutics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Entrada Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Entrada Therapeutics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship and minor.

  • Vertex PharmaceuticalsflagshipStrategic or Co-development Partner · 8 December 2022Global collaboration to develop Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1), including Entrada's lead candidate ENTR-701/VX-670. Entrada received $224 million upfront, $26 million equity investment, and is eligible for up to $485 million in milestone payments. Vertex is responsible for global development, manufacturing, and commercialization. The four-year research collaboration has Entrada advancing certain research activities related to VX-670 and additional DM1-related research. Program is in global Phase 1/2 development with enrollment and dosing underway.
  • Jett FoundationminorGTM or Marketing Partner2025 DREAMS Grant recipient — U.S.-based nonprofit headquartered in Massachusetts serving individuals affected by Duchenne muscular dystrophy. Grant funds Camp Promise year-round no-cost program for individuals aged 18+ living with Duchenne and other neuromuscular disorders.
  • Parent Project apsminorGTM or Marketing Partner2025 DREAMS Grant recipient — Italian nonprofit supporting individuals with Duchenne and Becker muscular dystrophy. Grant funds home-based care and teleconsultation services for families in underserved regions of Southern Italy.
  • CureDuchenneminorGTM or Marketing Partner2024 DREAMS Grant recipient supporting the CureDuchenne International Outreach Program to expand awareness, diagnosis, treatment and support for individuals affected by Duchenne in Nepal, Uganda, China and other countries throughout 2024-2025.
  • The Little Hercules Walking Strong Foundation (LHF)minorGTM or Marketing Partner2024 DREAMS Grant recipient supporting individualized case management services for the Duchenne community and subsidizing the cost of translation services for families whose first language is not English.
  • Walking StrongminorGTM or Marketing Partner2024 DREAMS Grant recipient expanding one-on-one mental wellness and life coaching, access to mobility and assistive devices, and canine support animals for individuals affected by Duchenne.
  • The Akari FoundationminorGTM or Marketing Partner2023 DREAMS Grant recipient — Hispanic-focused nonprofit educating and empowering the Hispanic community about rare diseases with a focus on Duchenne, providing resources, awareness, advocacy and education entirely in Spanish.
  • Neurology and Neuromuscular Care CenterminorGTM or Marketing Partner2023 DREAMS Grant recipient — nonprofit private practice led by Dr. Diana Castro providing care to neuromuscular patients from minority backgrounds who are underserved, uninsured or underinsured; grant funds hiring of first mental health professional.
  • Parent Project Muscular Dystrophy (PPMD) FoundationminorGTM or Marketing Partner2023 DREAMS Grant recipient — nonprofit patient advocacy organization fighting to end Duchenne by helping those living with the condition lead longer, stronger lives; grant supports work to address disparity in access to care and research opportunities.
  • Perkins School for the Blind — Perkins AccessminorImplementation/ SI/ Consulting PartnerDigital accessibility partner conducting user and expert reviews, WCAG 2.1 AA audits, role-based training, ongoing accessibility support and expert standards guidance for entradatx.com.
  • EDPO (European Data Protection Office) and EDPO UK LtdminorOthersGDPR / UK GDPR external data protection representatives appointed by Entrada Therapeutics. EDPO is the EU GDPR representative (Brussels, Belgium); EDPO UK Ltd is the UK GDPR representative (London, UK). Available for data subject requests via online forms.
  • Boston While Black; Latinos in Bio; Life Science Cares; OUTbio; Women In BiominorGTM or Marketing PartnerCommunity-based partner organizations supporting Entrada's diversity, equity, and inclusion initiatives across Boston, Cambridge, and the biotech sector. Provide community, mentorship, and challenge the status quo.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Entrada Therapeutics competitors and assessment

Company assessment

Direct peers

  • Sarepta Therapeutics: Sarepta is the leading commercial DMD franchise with approved exon-skipping PMOs (eteplirsen, golodirsen, casimersen) and Elevidys gene therapy. Directly comparable to Entrada as both companies develop exon-skipping oligonucleotide therapies for DMD populations including exons 44, 45, 50, and 51.
  • Avidity Biosciences: Avidity's antibody-oligonucleotide conjugate (AOC) platform has reported ~25% dystrophin production in DMD patients, setting the current competitive bar that Entrada's EEV-oligonucleotide approach must beat in the same exon-skipping populations.
  • Dyne Therapeutics: Dyne is developing oligonucleotide therapeutics for DMD using its FORCE™ platform targeting muscle. It is a direct competitor in exon-skipping DMD and shares Entrada's focus on muscle-targeted nucleic acid delivery.
  • PepGen: PepGen develops conjugated oligonucleotides for DMD and DM1 using its Enhanced Delivery Oligonucleotide (EDO) platform. Directly comparable to Entrada on modality (oligonucleotide) and on overlap in DMD and DM1 indications.
  • Solid Biosciences: Solid Biosciences is developing next-generation DMD therapies including SGT-003 (a gene therapy) and oligonucleotide approaches. It competes in the same DMD patient population targeted by Entrada's ENTR-601 series.
  • Capricor Therapeutics: Capricor is developing CAP-1002 (cell therapy) and deramiocel for DMD. It is a relevant comparable as a clinical-stage DMD company targeting the same patient population with a different therapeutic modality, competing for the same physician/patient mindshare and capital.

Broad incumbents

  • Vertex Pharmaceuticals: Vertex is Entrada's DM1 collaboration partner (VX-670) and a $26M equity holder. Comparable as a strategic partner/incumbent in DM1 and as a broader rare disease biopharma that could acquire Entrada or expand the relationship.
  • Ionis Pharmaceuticals: Ionis is the established antisense oligonucleotide platform company with multiple approved products (e.g., Spinraza for SMA). Comparable to Entrada on oligonucleotide modality and antisense approach, and as a potential acquirer of intracellular delivery technology.
  • BioMarin Pharmaceutical: BioMarin is an established rare disease biopharma with prior DMD exposure (Kyndrisa, discontinued) and a broad pipeline in neuromuscular and metabolic indications. Comparable as a larger incumbent that could partner with or acquire Entrada's EEV platform.

Emerging players

  • AMO Pharma: AMO Pharma is developing tideglusib for DM1 (Phase 2/3). Relevant emerging competitor in the DM1 indication that Entrada/Vertex's VX-670 also targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Entrada Therapeutics social profiles

Digital presence

Entrada Therapeutics compliance and trust

Trust signal

Compliance4 records

Entrada Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Entrada Therapeutics leadership team

Management profile

Number of profiles

Profiles13 records

Entrada Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Entrada Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Entrada Therapeutics M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Entrada Therapeutics

What does Entrada Therapeutics do?

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing intracellular therapeutics built on its proprietary Endosomal Escape Vehicle (EEV™) Platform — a library of cyclic cell-penetrating peptides engineered to deliver oligonucleotides and other therapeutic modalities into cells while escaping endosomal clearance. Its pipeline spans clinical-stage product candidates for Duchenne muscular dystrophy (ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51), the Vertex-partnered DM1 program VX-670/ENTR-701, and a discovery-stage program ENTR-801 for USH2A-related inherited retinal diseases.

Is Entrada Therapeutics a public or private company?

Entrada Therapeutics is a public company. It is classified as public and is currently operating.

When was Entrada Therapeutics founded?

Entrada Therapeutics was founded in 2017. It employs 101 to 250 people.

Where is Entrada Therapeutics based?

Entrada Therapeutics is headquartered in Boston, United States, in the North America region.

How does Entrada Therapeutics make money?

Two revenue lines are on record. Collaboration Revenue is the primary driver. The others are future Product Sales (Pipeline, Pre-Commercial).

Who are Entrada Therapeutics's main competitors?

Direct peers on record are Sarepta Therapeutics, Avidity Biosciences, Dyne Therapeutics, PepGen, Solid Biosciences and Capricor Therapeutics. Broad incumbents are Vertex Pharmaceuticals, Ionis Pharmaceuticals and BioMarin Pharmaceutical. AMO Pharma is listed as an emerging player.

Does Entrada Therapeutics have an API?

No public API is recorded for Entrada Therapeutics.

What industry is Entrada Therapeutics in?

Entrada Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 621991 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewEntrada Therapeutics (TRDA) DMC Recommends 15 mg/kg Cohort 3Entrada Therapeutics' Data Monitoring Committee recommended initiating Cohort 3 at 15 mg/kg after reviewing safety and PK data from eight Cohort 2 participants. Cohort 2 data are expected in H1 2027, with no prior-period comparison provided. The recommendation advances the Phase 1/2 study, but efficacy results are not disclosed.American Banking and Market NewsEntrada Therapeutics (NASDAQ:TRDA) Raised to “Hold” at Wall Street ZenWall Street Zen upgraded Entrada Therapeutics from Sell to Hold, while other firms gave mixed ratings. The stock opened at $4.89 with a market cap of $190.42 million. The company reported Q2 EPS of -$0.94, beating the -$0.98 consensus, but revenue of $0.91 million missed the $2.30 million estimate.YahooEntrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue EstimatesEntrada Therapeutics reported a Q3 loss of $0.94 per share, beating the consensus loss of $0.98, but revenue of $0.91 million missed estimates by 88.35%. The stock has fallen 50.8% year-to-date versus the S&P 500's 12.3% gain. Management's commentary will influence near-term price movement.Business & FinancialEntrada Therapeutics Reports Third Quarter 2026 Financial ResultsEntrada Therapeutics reported Q3 2026 results with a $39.7 million net loss and $193 million in cash, sufficient to fund operations into Q4 2027. The company highlighted positive safety data from ELEVATE-45-201 Cohort 1 and expects four clinical readouts through H1 2027.MarketBeatEntrada Therapeutics (NASDAQ:TRDA) Rating Lowered to "Sell" at Wall Street ZenWall Street Zen downgraded Entrada Therapeutics from 'hold' to 'sell' on Sunday. The stock opened at $4.53, with an average analyst rating of 'Hold' and a consensus target price of $17.75. The company reported a loss of $1.01 per share for the quarter, missing estimates.American Banking and Market NewsEntrada Therapeutics (NASDAQ:TRDA) Stock Gets Downgrade from Wall Street ZenWall Street Zen downgraded Entrada Therapeutics from hold to sell. The stock opened at $4.53, with an average analyst price target of $17.75. Major shareholders sold shares, and insiders have sold 714,013 shares in the last three months.MarketBeatEntrada Therapeutics (TRDA) Set to Announce Quarterly Earnings on ThursdayEntrada Therapeutics is set to announce Q3 2026 earnings on Thursday, November 5th, with analysts expecting a loss of $0.98 per share and revenue of $2.13 million. The company previously missed estimates with a loss of $1.01 per share and revenue of $0.90 million. Major shareholders have sold shares in recent weeks.MarketBeatEntrada Therapeutics (NASDAQ:TRDA) Stock Rating Raised to Hold at Wall Street ZenWall Street Zen raised Entrada Therapeutics from a sell to a hold rating. The stock has a consensus Hold rating with an average price target of $17.75, and the company reported a loss of $1.01 per share for the quarter, missing estimates.Business & FinancialEntrada Therapeutics Appoints Linea Aspesi As Chief People OfficerEntrada Therapeutics appointed Linea Aspesi as Chief People Officer. She brings over 20 years of experience scaling organizations, including roles at KalVista, Editas, and others. The company aims to build a culture to support its neuromuscular and genetic medicine pipeline.Stock TitanEntrada Therapeutics names Linea Aspesi chief people officerEntrada Therapeutics appointed Linea Aspesi as Chief People Officer to help scale its people and organization. Aspesi brings over 20 years of experience scaling organizations from discovery through commercial stages, including roles at KalVista, Editas, and others. The appointment aims to support Entrada's growth in neuromuscular programs.